Junior researchers

ახალგაზრდა მკვლევარები

Vol. 3 Issue 2, 2025

https://doi.org/10.52340/jr.2025.03.02.10

Mitochondrial Targeting by Resveratrol in Parkinson's Disease: A Multifaceted Approach Against Oxidative Damage and Neurodegeneration

Isha Ullal[1], Sana Sajed Pathan[2];

[1,2] Tbilisi State Medical University

CONTACT DETAILS: (move to end)

Isha Ullal: E-mail id: ullalisha02@gmail.com, Phone number: +995 595 77 34 91

ORCID ID: 0009-0006-6575-8607

Sana Sajed Pathan:

E-mail id: sanasajed02@gmail.com, Phone number: +995 599465196

ORCID ID: 0009-0006-7471-4307

INTRODUCTION:

Parkinson's Disease (PD) and other neurodegenerative diseases involve the progressive loss of neurons. Dysfunction of mitochondria, oxidative stress, and chronic inflammation are the principal mechanisms involved in the pathogenesis of such diseases. Neurons have high metabolic activity and limited regeneration capacity; therefore, they are particularly sensitive to oxidative damage. Mitochondria, only ATP generators for the cell through oxidative phosphorylation, also produce reactive oxygen species (ROS) as byproducts. When produced in excess amounts, ROS cause oxidative stress that leads to damaged mitochondria and then neuronal apoptosis this is how PD progresses.

In the past few years, resveratrol (trans-3,5,4'-trihydroxystilbene) has been discovered as a natural polyphenol from red grapes, berries, peanuts, and red wine with great potential as a neuroprotective agent. Apart from its long-known antioxidant activity it has been recognized for its antioxidant, anti-inflammatory, & cardioprotective properties. More recently, it has been in the spotlight for its potential for neuroprotection in neurodegenerative diseases, including Parkinson's Disease (PD). While classified as a nutraceutical, its mechanisms have made it an increasing area of research. Its main neuroprotective mechanism is counteracting oxidative stress, one of the main factors involved in PD pathogenesis. Through oxidative phosphorylation, mitochondria generate reactive oxygen species (ROS), which in high levels lead to oxidative damage, mitochondrial dysfunction, and neuronal death.

Resveratrol acts as an antioxidant by neutralizing free radicals, decreasing ROS, and blocking complex III of the mitochondrial electron transport chain, and activating antioxidant enzymes.

METHODOLOGY:

In this review, 18 preclinical studies were evaluated regarding the therapeutic efficacy of resveratrol in rodent models of Parkinson's Disease (PD). These used chemically induced and transgenic models to replicate the neuropathology of PD. Chemically induced models involved neurotoxins such as MPTP, rotenone, and 6-hydroxydopamine (6-OHDA), along with paraquat and maneb; all induce loss of dopaminergic neurons as well as oxidative stress and mitochondrial dysfunction—criteria for PD. The transgenic models reproduced genetic and pathological features corresponding to familial forms of the disease.

Across these models, resveratrol was able to demonstrate its neuroprotective effects. The significant results were the improvement of motor function, reduction of oxidative stress and neuroinflammation, and preservation of mitochondrial integrity. Mechanistic studies centered on its function in increasing mitochondrial biogenesis, managing the equilibrium of mitochondrial fusion and fission, enhancing antioxidant enzyme activity, facilitating mitophagy via SIRT1 and AMPK/ERK pathways, and adjusting apoptotic signaling. The evidence underscores resveratrol's promise as a treatment for safeguarding dopaminergic neurons and reducing the progression of PD



Figure 1: Resveratrol's role in protecting mitochondria in Parkinson's disease (PD) pathogenesis. Normally, mitochondrial bioenergetics relies on oxidative phosphorylation (OXPHOS) in the inner membrane to produce ATP. During OXPHOS, electron leakage—mainly from complexes I and III—generates superoxide radicals (O2•–), which can disrupt Ca2+ balance, damage mitochondrial DNA (mDNA), and trigger mitochondria-dependent apoptosis under excessive oxidative stress. Antioxidant defenses in mitochondria include Mn-SOD (SOD2), glutathione peroxidase (GPX), and peroxiredoxin (PRX). Resveratrol (RSV) confers neuroprotection by: (1) scavenging ROS and enhancing endogenous antioxidant enzyme activity; (2) activating the SIRT-1–AMPK pathway, promoting mitochondrial biogenesis via PGC-1α, Nrf1/2, and TFAM; (3) stimulating AMPK and inhibiting mTOR, thereby activating ULK1 to initiate autophagy/mitophagy and suppressing mitochondrial apoptosis; (4) reducing α-synuclein (α-syn) aggregation. Abbreviations: ROS, reactive oxygen species; Mn-SOD/SOD2, manganese superoxide dismutase; SIRT-1, sirtuin 1; AMPK, adenosine monophosphate-activated protein kinase; PGC-1α, PPARγ coactivator-1α; Nrf1/2, nuclear respiratory factors 1/2; TFAM, mitochondrial transcription factor A; mTOR, mechanistic target of rapamycin; ULK1, Unc-51-like kinase 1; GPX, glutathione peroxidase; HO-1, heme oxygenase-1; Δψm, mitochondrial membrane potential; VDAC, voltage-dependent anion channel; MCU, mitochondrial calcium uniporter; NCLX, mitochondrial Na+/Li+/Ca2+ exchanger; Bak, Bax, MAC, MOMP, cyt c, IMS, MIM—components of mitochondrial apoptosis pathways.

RESULTS:

Five studies demonstrated that resveratrol preserved dopaminergic neurons in both the substantia nigra and striatum.Tyrosine hydroxylase (TH) expression was increased, suggesting improved dopaminergic activity, and motor behavior was improved. Resveratrol decreased the production of reactive oxygen species (ROS) and increased mitochondrial efficiency, according to several studies. It continuously reduced lipid peroxidation indicators like malondialdehyde (MDA) and increased endogenous antioxidant enzymes including glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD).

Multiple studies showed its anti-inflammatory function by significantly reducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. These effects were associated with a decline in microglial activation and glial inflammation. According to mechanistic studies, resveratrol influenced apoptotic pathways, as demonstrated by decreased expression of pro-apoptotic indicators Bax and caspase-3 and elevated levels of the anti-apoptotic protein Bcl-2. Additionally, by activating the SIRT1 and AMPK/ERK signaling pathways, resveratrol increased mitophagy and helped to maintain mitochondrial homeostasis.

The results of a meta-analysis confirmed these conclusions. Significant improvements in motor coordination ($p < 0.01$), TH-positive neuron survival ($p < 0.05$), and oxidative stress biomarker reduction ($p < 0.01$) were observed in treated groups. Overall, SYRCLE's risk of bias assessment showed a moderate level of methodological quality, with several issues pertaining to unclear or high risk of bias in the allocation and blinding procedures. The combined data support resveratrol's neuroprotective efficacy in preclinical PD models, despite variability.

DISCUSSIONS:

Natural chemicals have gained attention as potential treatments for neurodegenerative illnesses, especially Parkinson's disease (PD), where chronic oxidative stress and gradual loss of dopaminergic neurons are key factors. Resveratrol is one of these substances that has demonstrated encouraging neuroprotective potential in preclinical settings.

18 research using different PD models, including as MPTP, 6-OHDA, rotenone, were included in this review. Key clinical characteristics of Parkinson's disease (PD), including oxidative damage, mitochondrial dysfunction, neuroinflammation, and dopaminergic cell loss, were consistently replicated by these models. Resveratrol continuously enhanced motor function and histopathological results across mice.

Tyrosine hydroxylase (TH)-positive neurons were significantly preserved in resveratrol-treated groups, according to meta-analytic data, especially in MPTP and 6-OHDA models. Its neuroprotective

potential was further supported by functional improvements in motor evaluations that coincided with this.

Resveratrol seems to have several mechanisms of action. It increased endogenous antioxidants including SOD, CAT, and GSH while decreasing oxidative stress indicators like ROS and MDA. Numerous investigations have reported decreases in pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), most likely as a result of altered microglial activation. It also increased mitochondrial biogenesis, maintained mitochondrial integrity, and decreased apoptotic signaling through the upregulation of Bcl-2 and the suppression of Bax and caspase-3. Its multi-targeted action is further supported by its involvement in signaling pathways like SIRT1/PGC-1α, AMPK, and PI3K/Akt.

Notably, response varied by model: rotenone and 6-OHDA models showed stronger evidence of mitochondrial support and anti-apoptotic pathways, whereas MPTP models mainly emphasized antioxidative and anti-inflammatory benefits.

CONCLUSIONS:

In conclusion, resveratrol demonstrates strong neuroprotective potential in preclinical PD models by targeting oxidative stress, mitochondrial dysfunction, and defective autophagy. The antioxidant effect of Resveratrol coupled with the stimulation of mitophagy through AMPK and SIRT1, in addition to support for mitochondrial biogenesis, works well in preserving dopaminergic neurons leading to better motor outcomes. This modulation of redox and mitochondrial dynamics positions resveratrol as a promising multi-target agent for neurodegenerative interventions. However, exact mechanisms in human neurodegeneration remain underexplored.have not been extensively explored. There has been no clinical validation of these findings which stresses the importance of translational studies that bridge preclinical success with therapeutic application. As a safe, naturally derived compound with broad activity, resveratrol holds transformative potential for PD and as a prototype for polyphenol-based neurotherapeutics in other neurodegenerative and chronic diseases.

KEYWORDS

Resveratrol, Parkinson's Disease, Oxidative Stress, Mitochondrial Dysfunction, Neuroprotection, Dopaminergic Neurons, Antioxidant Pathways, Mitophagy, SIRT1, AMPK, Polyphenols, Neurodegeneration, PD animal models, Literature Review

REFERENCES:

1. Kung, H., Lin, K., Kung, C., & Lin, T. (2021). Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson's Disease. *Biomedicines*, *9*(8), 918.

2. Danışman, B., Kelek, S. E., & Aslan, M. (2023). Resveratrol in neurodegeneration, in neurodegenerative diseases, and in the redox biology of the mitochondria. *Psychiatry and Clinical Psychopharmacology*, 147–155.

3. Su, C., Jiang, L., Zhang, X., Iyaswamy, A., & Li, M. (2021). Resveratrol in rodent models of Parkinson's disease: A systematic review of experimental studies. *Frontiers in Pharmacology*, *12*.

4. Ferretta, A., Gaballo, A., Tanzarella, P., Piccoli, C., Capitanio, N., Nico, B., Annese, T., Di Paola, M., Dell'Aquila, C., De Mari, M., Ferranini, E., Bonifati, V., Pacelli, C. and Cocco, T. (2014). Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson's disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1842(7), pp.902–915.67